7 years ago

Enterprise Therapeutics Secures £29M Series B Funding to Advance Respiratory Therapies

  • Enterprise Therapeutics, a Brighton, England-based biopharmaceutical company developing therapies for respiratory diseases, raised £29 million in Series B funding led by Versant Ventures and Novartis Venture Fund

  • The round also included new investor Forbion, founding investor Epidarex Capital, and existing investor IP Group

  • Enterprise Therapeutics intends to use the funds to advance its drug discovery pipeline of muco-regulatory therapies into clinical development

  • These therapies target the ion channels TMEM16A and ENaC to increase mucus hydration and clearance, as well as novel targets and compounds that reduce mucus production.

      • ProblemHealthcare

      "difficulty in breathing and recurrent lung infections caused by mucus obstruction in respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, and severe asthma."

      Solution

      "developing muco-regulatory therapies that target the ion channels TMEM16A and ENaC to increase the hydration and clearance of mucus, and also identifying novel targets and compounds that reduce mucus production"

      Covered on